A novel anti-PD-L1/IL-15 immunocytokine overcomes resistance to PD-L1 blockade and elicits potent antitumor immunity
This study develops an immunocytokine (LH01) combining anti-PD-L1 and IL-15 to enhance antitumor immunity and overcome resistance to PD-L1 blockade in mouse models.